Stifel Nicolaus reiterated their buy rating on shares of Hologic, Inc. (NASDAQ:HOLX) in a research note published on Monday morning, Marketbeat.com reports. Stifel Nicolaus currently has a $45.00 price objective on the medical equipment provider’s stock, down from their prior price objective of $48.00.

A number of other research firms have also recently commented on HOLX. Jefferies Group LLC reissued a buy rating and issued a $49.00 target price on shares of Hologic in a research note on Wednesday, June 28th. Bank of America Corporation reissued a neutral rating and issued a $48.00 target price (up from $44.00) on shares of Hologic in a research note on Friday, July 21st. Piper Jaffray Companies reissued a buy rating and issued a $51.00 target price on shares of Hologic in a research note on Friday, July 14th. BidaskClub cut Hologic from a strong-buy rating to a buy rating in a research note on Tuesday, July 25th. Finally, Barclays PLC reissued an overweight rating and issued a $53.00 target price (up from $50.00) on shares of Hologic in a research note on Monday, July 17th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of Hold and an average target price of $47.77.

Hologic (NASDAQ HOLX) opened at 36.56 on Monday. The firm’s 50-day moving average price is $37.69 and its 200 day moving average price is $41.94. The company has a market capitalization of $10.25 billion, a PE ratio of 13.62 and a beta of 0.91. Hologic has a 52 week low of $35.15 and a 52 week high of $46.80.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The firm had revenue of $806.10 million for the quarter, compared to analysts’ expectations of $799.70 million. During the same period in the prior year, the firm posted $0.51 earnings per share. The company’s quarterly revenue was up 12.4% on a year-over-year basis. Equities research analysts expect that Hologic will post $2.01 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/10/13/hologic-inc-holx-given-buy-rating-at-stifel-nicolaus.html.

In other Hologic news, Director Lawrence M. Levy sold 7,139 shares of the stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $39.04, for a total value of $278,706.56. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Karleen Marie Oberton sold 4,704 shares of the stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $45.19, for a total value of $212,573.76. The disclosure for this sale can be found here. In the last three months, insiders sold 35,479 shares of company stock worth $1,388,236. 0.79% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the business. Picton Mahoney Asset Management lifted its holdings in Hologic by 8.1% in the second quarter. Picton Mahoney Asset Management now owns 57,150 shares of the medical equipment provider’s stock valued at $2,593,000 after acquiring an additional 4,300 shares during the period. Russell Investments Group Ltd. lifted its holdings in Hologic by 229.7% in the second quarter. Russell Investments Group Ltd. now owns 1,059,586 shares of the medical equipment provider’s stock valued at $48,100,000 after acquiring an additional 738,215 shares during the period. Swiss National Bank lifted its holdings in Hologic by 12.8% in the second quarter. Swiss National Bank now owns 1,159,424 shares of the medical equipment provider’s stock valued at $52,615,000 after acquiring an additional 131,300 shares during the period. Rhumbline Advisers lifted its holdings in Hologic by 1.4% in the second quarter. Rhumbline Advisers now owns 548,465 shares of the medical equipment provider’s stock valued at $24,889,000 after acquiring an additional 7,727 shares during the period. Finally, Scout Investments Inc. lifted its holdings in Hologic by 31.3% in the second quarter. Scout Investments Inc. now owns 620,084 shares of the medical equipment provider’s stock valued at $28,139,000 after acquiring an additional 147,929 shares during the period. 96.38% of the stock is currently owned by institutional investors.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.